Study Evaluating the Gastrointestinal Safety of PLA-695 Compared to Placebo and Naproxen

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to provide an initial assessment of the gastrointestinal safety of a 7-day regimen of PLA-695 compared to placebo or naproxen.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Naproxen

Criteria

Inclusion Criteria:

• Healthy men or women of nonchildbearing potential, aged 18 to 60 years.

Exclusion Criteria:

• Abnormal baseline endoscopy.

• Positive Helicobacter pylori serology.